Publishing options:
Irish Consortium of universities associated authors
Welcome Mr.

To help us finalize the publication of your article, please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

- **Purchase Order Number**
  
  If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.

- **Tax Exemption Number** and **Tax Exemption Certificate** if applicable to your institution.

For Bank and company address details, see the Information you may need to supply to complete the options.

---

**Rights and Access**

**Complete the Rights and Access information form**

Elsevier supports responsible sharing. To find out how you can share your article, please visit our Sharing Policy page.

For information on author rights visit Elsevier’s Author Rights pages.

For information on publishing open access with Elsevier visit elsevier.com/openaccess.
• Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Ireland agreement.

• In this case, the author is affiliated with ‘University College Dublin’.
Corresponding author also adds the co-author affiliation details.

Were there any co-authors for this article?
- Yes
- No

Add Co-author Details

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start the organization search using the main organisation name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you’re unable to find the specific department, then selecting the main organization is sufficient.

For more tips on searching for an organization please visit our Support Center.

First name or initial*
Morgan

Last name*
Eoin

Organization name*
University of Limerick

Or use recently selected organization
University College Dublin

† Add another co-author
Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case it is Milliman

Did the research in this article receive funding?
- Yes
- No

Funder Details
Please provide details of the organization(s) that funded the research. For tips on searching for an organization please visit our Support Center.

If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.

Organization name
Milliman

Grant/Contract numbers
GT123

+ Add grant/contract number

+ Add another organization
Based on the corresponding author affiliation details, the author sees the IReL Publishing Options. Gold OA option is followed by Subscription option and we make it clear that agreement covers full APC.

If the librarian at the consortium rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice.

In a Hybrid journal, the author can change the article to subscription by contacting support@elsevier.com within 2 weeks in case they cannot pay for OA.

We will update the text in asterisk under Gold OA option by mid February 2020.

Author selects Gold OA.
In case of OA, author selects the CC License

Author selects CC BY license in this case
System presents author with the Journal License Publishing Agreement

Author journey demo: 27

Elsevier Ltd

Your Status

• I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier Ltd an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Supplemental Materials

“Supplemental Materials” shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier Ltd shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.
Authors agrees to 
the Journal License 
Publishing 
Agreement

- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors’ institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher’s policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminates or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Ltd (“the Governing State”), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher’s copyright and access policies, please see http://www.elsevier.com/copyright.

☐ I have read and agree to the terms of the License Agreement.

20 January 2020

T-copyright license-v5/2017
This is the summary page explaining the choices the author made in the publishing journey.

Corresponding author and coauthors receive a copy of summary via email.

Upon clicking ‘Finish’ Librarian at the institute will receive a notification for validation.

| Research Funders | Milliman  
| Grant numbers: GT123 |
| Publishing Option | Gold Open Access * |
| User License | CC BY 4.0 |

Publishing Agreement

- I am one author signing on behalf of all co-authors of the manuscript.

I may share my final published article widely in accordance with the user License that I have selected. Further details on Elsevier Sharing Policy here.

*If the validation is not successful, an invoice for the total APC of EUR 3,220.00 (ex. tax) will be sent directly to me.

20 January 2020
Thank you